戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uding prasugrel, ticagrelor, and intravenous cangrelor.
2 eeding episodes were numerically higher with cangrelor.
3 e similar in both women and men treated with cangrelor (0.3% versus 0.2%, P=0.30 [women]; 0.1% versus
4  clopidogrel group (adjusted odds ratio with cangrelor, 0.78; 95% confidence interval [CI], 0.66 to 0
5 9, 100 micromol/L) and especially P(2)Y(12) (Cangrelor, 10 micromol/L) blunted CXCL16-triggered plate
6 t occurred in 185 of 2654 patients receiving cangrelor (7.0%) and in 210 of 2641 patients receiving p
7 rivative (a specific P2X(1) antagonist), and cangrelor (a specific P2Y(12) antagonist) mitigated the
8 on Triage Strategy criteria) was higher with cangrelor, a difference that approached statistical sign
9                                              Cangrelor, a nonthienopyridine adenosine triphosphate an
10                                  Intravenous cangrelor, a rapid-acting, reversible adenosine diphosph
11 ee trials that assessed the effectiveness of cangrelor against either clopidogrel or placebo in PCI.
12 significantly lower in patients treated with cangrelor alone (0.7% vs 2.4%; OR, 0.29; 95% CI, 0.13-0.
13 were not significantly different between the cangrelor alone and clopidogrel-GPI groups (2.6% vs 3.3%
14 efined severe/life-threatening bleeding with cangrelor alone compared with clopidogrel-GPI (0.3% vs 0
15 analysis from the 3 phase 3 CHAMPION trials, cangrelor alone was associated with similar ischemic ris
16 ssigned to cangrelor but not receiving GPIs (cangrelor alone) and 1211 patients assigned to clopidogr
17                                              Cangrelor, an intravenous, reversible P2Y12 antagonist,
18 event >1 year old, including 650 assigned to cangrelor and 620 assigned to clopidogrel.
19  P2Y12 and alphaIIbbeta3 receptor inhibitors cangrelor and abciximab, respectively, both in vitro--by
20 aracteristics were well balanced between the cangrelor and clopidogrel arms in subsets receiving and
21 0.6%) and 54 of 5,469 (1.0%) patients in the cangrelor and clopidogrel arms, respectively (odds ratio
22 11.8% (12 of 102) vs 10.4% (10 of 96) in the cangrelor and placebo groups, respectively (RR, 1.1 [95%
23  of GPR17 by the marketed antiplatelet drugs cangrelor and ticagrelor, previously suggested to antago
24 el P2Y12 antagonists (prasugrel, ticagrelor, cangrelor, and elinogrel) that have advantages over clop
25  triethylammonium salt hydrate (2MeSAMP) and Cangrelor (AR-C69931MX) have been widely used to demonst
26 icipants included 10929 patients assigned to cangrelor but not receiving GPIs (cangrelor alone) and 1
27 ation showed a trend toward a reduction with cangrelor, but it was not significant (0.6% vs. 0.9%; od
28 linical Trial to Demonstrate the Efficacy of Cangrelor), CHAMPION PLATFORM (Cangrelor Versus Standard
29 e primary composite endpoint were lower with cangrelor compared with clopidogrel in patients who did
30 ought to evaluate the efficacy and safety of cangrelor compared with clopidogrel in subgroups that di
31                                              Cangrelor compared with clopidogrel significantly reduce
32 ention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that
33 therapy prior to cardiac surgery, the use of cangrelor compared with placebo resulted in a higher rat
34  large global cardiovascular clinical trial, cangrelor consistently reduced rates of ischemic end poi
35 nduces food intake, whereas Gpr17 antagonist cangrelor curtails it.
36                                  The dose of cangrelor determined in 10 patients in the open-label st
37                                              Cangrelor did not increase the primary safety endpoint,
38                    The use of periprocedural cangrelor during PCI was not superior to placebo in redu
39  forskolin) of the cAMP pathway, 2MeSAMP and Cangrelor failed to inhibit Ca(2+) mobilization, Akt pho
40 roduction of an intravenous P2Y12 inhibitor (cangrelor) further adds to the multitude of modalities a
41 he primary safety end point was 0.16% in the cangrelor group and 0.11% in the clopidogrel group (odds
42 n the rate of blood transfusion (1.0% in the cangrelor group and 0.6% in the placebo group, P=0.13),
43 e primary efficacy end point was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (adjus
44 t, which occurred in 7.5% of patients in the cangrelor group and 7.1% of patients in the clopidogrel
45 sis developed in 0.8% of the patients in the cangrelor group and in 1.4% in the clopidogrel group (od
46 e primary efficacy end point was 4.3% in the cangrelor group versus 5.3% in the clopidogrel group (od
47  receiving placebo (8.0%) (odds ratio in the cangrelor group, 0.87; 95% confidence interval [CI], 0.7
48                                       In the cangrelor group, as compared with the placebo group, two
49 r bleeding on one scale was increased in the cangrelor group, from 3.5% to 5.5% (P<0.001), because of
50 stent thrombosis and death were lower in the cangrelor group, with no significant increase in the rat
51  greater proportion of patients treated with cangrelor had low levels of platelet reactivity througho
52 end point, stent thrombosis, were reduced by cangrelor in both regions.
53 imary efficacy and safety end point) favored cangrelor in both women (OR, 0.68; 95% CI, 0.50-0.92) an
54  were low and not significantly increased by cangrelor in either region.
55 N) PHOENIX trial demonstrated superiority of cangrelor in reducing ischemic events at 48 hours in pat
56 s GUSTO moderate/severe bleeding, the OR for cangrelor in those >/=75 years old was 0.75 (6.4% versus
57 bitors (GPIs) and a potent P2Y12 antagonist, cangrelor, in patients undergoing PCI.
58 0.4%), or in transfusion (0.7% vs 0.6%), but cangrelor increased GUSTO mild bleeding (16.8% vs 13.0%,
59                                              Cangrelor increased the odds of moderate bleeding in wom
60 evealed that neither 2MeSAMP nor ARC69931MX (cangrelor) increased cAMP through activation of A2a, IP,
61 lucidate the mechanisms by which 2MeSAMP and Cangrelor inhibit platelet activation and thrombosis.
62 e data together demonstrate that 2MeSAMP and Cangrelor inhibit platelet function through the P2Y(12)-
63                                  2MeSAMP and Cangrelor inhibited aggregation and ATP release of wild-
64              Importantly, while injection of Cangrelor inhibited thrombus formation in a FeCl(3)-indu
65                                              Cangrelor is a potent intravenous adenosine diphosphate
66                                              Cangrelor is a potent intravenous adenosine diphosphate-
67                                              Cangrelor is a potent, rapid-acting, reversible intraven
68                                              Cangrelor is an intravenous ADP receptor antagonist that
69                                              Cangrelor is an intravenous P2Y12 inhibitor approved to
70                                              Cangrelor is being evaluated in clinical trials of throm
71 rther study of intravenous ADP blockade with cangrelor may be warranted.
72                                  2MeSAMP and Cangrelor neither raised intracellular cAMP concentratio
73                                The effect of cangrelor on ischemic events and bleeding was analyzed i
74 r total MIs (n=134); however, the effects of cangrelor on MI remained significant (OR, 0.65; 95% CI,
75 ere seen in the evaluation of the effects of cangrelor on MIs with peak creatinine kinase-MB >/=10 ti
76                   We explored the effects of cangrelor on myocardial infarction (MI) using different
77  total of 11 145 patients were randomized to cangrelor or clopidogrel in the CHAMPION PHOENIX trial (
78 ition) PHOENIX randomized 11 145 patients to cangrelor or clopidogrel.
79 urgent percutaneous coronary intervention to cangrelor or clopidogrel.
80 ng rates, regardless of the randomization to cangrelor or clopidogrel.
81 dine awaiting CABG surgery to receive either cangrelor or placebo after an initial open-label, dose-f
82 n treated with clopidogrel to receive either cangrelor or placebo at the time of PCI, followed by 600
83  were stopped and patients were administered cangrelor or placebo for at least 48 hours, which was di
84 d therapy to receive a bolus and infusion of cangrelor or to receive a loading dose of 600 mg or 300
85 linical Trial to Demonstrate the Efficacy of Cangrelor [PCI]: NCT00305162; Cangrelor Versus Standard
86  recent study reported that both 2MeSAMP and Cangrelor raise intra-platelet cAMP levels and inhibit p
87 pared with control (clopidogrel or placebo), cangrelor reduced PCI periprocedural thrombotic complica
88                                              Cangrelor reduced rates of the primary composite end poi
89                               Treatment with cangrelor reduced the composite end point of death, MI (
90                               Treatment with cangrelor reduced the incidence of MI at 48 hours (3.8%
91                         In CHAMPION PHOENIX, cangrelor reduced the odds of major adverse cardiovascul
92                                              Cangrelor reduced the odds of stent thrombosis by 61% in
93                                              Cangrelor reduced the odds of the primary end point by 3
94                                              Cangrelor reduced the odds of the primary outcome by 19%
95                                              Cangrelor reduced the odds of the secondary triple compo
96                                              Cangrelor resulted in directionally consistent effects o
97                                              Cangrelor's efficacy in reducing ischemic complications
98 e Percutaneous Coronary Intervention) trial, cangrelor significantly reduced periprocedural and 30-da
99                                              Cangrelor significantly reduced the rate of ischemic eve
100 intravenous adenosine diphosphate antagonist cangrelor substantially reduced IPST, contributing to it
101  occurred significantly more frequently with cangrelor than with clopidogrel (1.2% vs. 0.3%).
102 d CHAMPION PHOENIX (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Sub
103                    (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Sub
104 RM]: NCT00385138; A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Wh
105 CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Wh
106 rence in GUSTO moderate/severe bleeding with cangrelor versus clopidogrel (1.1% versus 1.0%; OR, 1.07
107 he Efficacy of Cangrelor [PCI]: NCT00305162; Cangrelor Versus Standard Therapy to Achieve Optimal Man
108                        METHODS AND CHAMPION (cangrelor versus standard therapy to achieve optimal man
109 e Efficacy of Cangrelor), CHAMPION PLATFORM (Cangrelor Versus Standard Therapy to Achieve Optimal Man
110 r clopidogrel in the CHAMPION PHOENIX trial (Cangrelor versus Standard Therapy to Achieve Optimal Man
111                                          The Cangrelor Versus Standard Therapy to Achieve Optimal Man
112                                          The Cangrelor versus Standard Therapy to Achieve Optimal Man
113 d, patient-level analysis of the 3 CHAMPION (Cangrelor versus Standard Therapy to Achieve Optimal Man
114 odds of the primary outcome by 19% (3.8% for cangrelor vs 4.7% for control; odds ratio [OR] 0.81, 95%
115 pooled patient-level data from the 3 phase 3 Cangrelor vs Standard Therapy to Achieve Optimal Managem
116 , double-blind, double-dummy trials in which cangrelor was compared with clopidogrel during percutane
117                                    Likewise, cangrelor was not superior at 30 days.
118                                 At 48 hours, cangrelor was not superior to clopidogrel with respect t
119                                              Cangrelor, when administered intravenously 30 minutes be
120                                              Cangrelor, when compared with clopidogrel, provides simi
121  a large-scale international trial comparing cangrelor with 600 mg of oral clopidogrel administered b
122 ION-PLATFORM, and CHAMPION-PHOENIX) compared cangrelor with control (clopidogrel or placebo) for prev
123                             The benefit from cangrelor with respect to the primary end point was cons
124 t P2Y12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/I

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top